UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
The current clinical trial uses an aqueous UGN-501 formulation without RTGel.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UroGen Pharma (URGN) has dosed the first patient in its Phase 1 trial of UGN-501 for recurrent non-muscle invasive bladder cancer.
The trial evaluates administration directly into the bladder, focusing on safety, tolerability and pharmacokinetics, or how the treatment behaves in the body, and determining a recommended Phase 2 dose. The open-label, dose-escalation study includes adults with high-grade Ta/T1 disease and/or carcinoma in situ, or low-grade Ta/T1 disease. All visible papillary tumors must be removed and obvious carcinoma in situ areas destroyed before treatment. UroGen is also conducting nonclinical studies exploring UGN-501 formulated with its RTGel technology.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFirst patient dosed advances UGN-501 from nonclinical research into Phase 1 clinical evaluation.
- Minor pointParallel nonclinical studies are exploring UGN-501 formulation with UroGen's RTGel technology.
Negative
- None.
News Explained
The current Phase 1 trial uses aqueous UGN-501 without RTGel, while UroGen is separately exploring RTGel formulations in nonclinical studies; thus, the patient dosing announced here tests the aqueous version, not the RTGel formulation.
Key Figures
- Induction instillations
- Six once-weekly instillations
- UGN-501 Phase 1 trial
- Induction period
- 12 weeks
- Treatment induction
- Maintenance instillations
- Three once-weekly instillations
- Administered quarterly from month three through month 12 for eligible participants
- Safety follow-up
- Month 15
- Trial follow-up visit
Key Terms
intravesical medical
pharmacokinetics medical
dose-escalation medical
carcinoma in situ medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Phase 1 clinical trial to evaluate local intravesical administration of UGN-501
- UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation
PRINCETON, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the first patient was dosed with UGN-501, a next-generation investigational oncolytic virus. The Phase 1 trial will evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501.
“The first patient dosed with UGN-501 marks an important step in advancing this investigational therapy from nonclinical research into clinical evaluation,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “We can now begin to understand its safety and tolerability in patients with NMIBC and generate insights to guide its continued development. This progress brings us closer to our goal of expanding treatment options for patients with bladder cancer.”
The Phase 1, open-label, dose-escalation trial is designed to evaluate the safety, tolerability and pharmacokinetics of intravesically administered UGN-501 and determine the recommended Phase 2 dose in adults with recurrent non-muscle invasive bladder cancer (NMIBC), including high-grade Ta/T1 disease and/or carcinoma in situ (CIS), or low-grade Ta/T1 disease. Before treatment, all visible papillary tumors must be resected and obvious areas of CIS fulgurated. Participants will receive an aqueous formulation of UGN-501 through six once-weekly intravesical instillations during a 12-week induction period. Participants with no evidence of disease at week 12 may proceed to maintenance treatment consisting of three once-weekly instillations administered quarterly from month three through month 12, or until disease recurrence, disease progression or death, whichever occurs first, with a safety follow-up visit at month 15. For more information about the Phase 1 trial, go to ClinicalTrials.gov at NCT07725796.
In parallel with the Phase 1 trial, UroGen is conducting nonclinical studies exploring the formulation of UGN-501 in its proprietary RTGel® technology. The formulation being evaluated in the current Phase 1 trial is aqueous and does not contain RTGel.
NMIBC continues to present significant clinical challenges, particularly among patients whose disease recurs following standard treatment. Despite available therapies, recurrence rates remain substantial, underscoring the need for novel bladder-sparing therapeutic approaches. UroGen believes UGN-501's differentiated mechanism of action and local administration strategy may offer a promising new approach for addressing this unmet need.
About UGN-501
UGN-501 is an investigational, next-generation oncolytic virus being investigated for the treatment of non-muscle invasive bladder cancer (NMIBC). UGN-501 is designed to selectively replicate within tumor cells, resulting in direct tumor cell destruction and an anti-tumor immune response. The program is supported by nonclinical data demonstrating cytotoxic activity across a broad panel of bladder cancer cell lines representing multiple stages and grades of disease. While UGN-501 is initially being developed for bladder cancer, the Company believes UGN-501's underlying properties may have broader applicability across additional solid tumor indications and intends to evaluate future development opportunities based on emerging clinical and translational data.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product to treat adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Visit www.UroGen.com to learn more or follow us on X (formerly Twitter), @UroGenPharma.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the progress and plans for the Phase 1 clinical trial of UGN-501 in NMIBC; UroGen’s nonclinical studies exploring the formulation of UGN-501 in its proprietary RTGel technology; the design and potential benefits of UGN-501, including to selectively replicate within tumor cells, resulting in direct tumor cell destruction and an anti-tumor immune response, and its differentiated mechanism of action and local administration strategy potentially offering a promising new approach for addressing un unmet need; UGN-501’s potential for broader applicability across additional solid tumor indications; UroGen’s plans to evaluate future development opportunities for NMIBC based on emerging clinical and translational data; the belief that UGN-501 has several attributes that differentiate it from other oncolytic viruses; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs or UGN-501 and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “believe,” “can,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: nonclinical results may not be indicative of results that may be observed in clinical trials; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected, including when formulated with UGN-501; UroGen’s financial condition and need for additional capital; and UroGen may not successfully develop and receive regulatory approval of a product candidate, including ones that incorporate RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 5, 2026 (which is available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
INVESTOR:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is UroGen's Phase 1 UGN-501 trial evaluating?
The trial evaluates safety, tolerability and pharmacokinetics of UGN-501 administered directly into the bladder and aims to determine a recommended Phase 2 dose. It is an open-label, dose-escalation study in adults with recurrent non-muscle invasive bladder cancer.
What is the treatment schedule in UroGen's UGN-501 trial?
Participants receive six once-weekly bladder instillations during a 12-week induction period. Those with no evidence of disease at week 12 may receive maintenance treatment: three once-weekly instillations administered quarterly from month three through month 12, or until disease recurrence, disease progression or death, whichever occurs first. A safety follow-up visit occurs at month 15.
Does UroGen's Phase 1 UGN-501 trial use RTGel?
The current Phase 1 trial uses an aqueous formulation without RTGel. UroGen is separately conducting nonclinical studies exploring UGN-501 formulated with its proprietary RTGel technology.